NK-Activity PBMC

Our NK-Activity ePBMC® have been characterized for cytolytic activity against K562 tumor cells.

 

Available in ≥10 million cells per vial.

 

 


Learn more about ePBMC®.

View % of Killing Effector:Target Ratios

NK-TVA™ Platform

Search Database


 
Click to view details
NK-Activity PBMC

CTL Europe GmbH 
Hans-Boeckler-Str. 19-29 | 53225 Bonn, Germany
+49 228 85 44 78-0 | +49 228 85 44 78-22 Fax                     
Privacy Policy | Legal Note | Sitemap
ctl-europe@immunospot.eu | www.immunospot.eu

© 2017 CTL Europe GmbH